Brief: Cipla Says USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
10/02/2026 05:43
Feb 10 (Reuters) - Cipla Ltd CIPL.NS: CIPLA - USFDA INSPECTION AT INVAGEN MANUFACTURING FACILITY IN HAUPPAUGE, LONG ISLAND, NEW YORK, USA CIPLA - ON CONCLUSION OF INSPECTION, INVAGEN HAS RECEIVED 2 INSPECTIONAL OBSERVATIONS Source text: ID:nNSEb8YkN0 Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate